DeepMed Research

Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Clinical Trials

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Fruquintinib + RC48

First Posted Date: 2022-02-16

Last Posted Date: 2022-02-16

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 56

Registration Number: NCT05241899

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Fruquintinib Hepatic Impairment Study

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Fruquintinib

First Posted Date: 2022-01-31

Last Posted Date: 2022-10-31

Lead Sponsor: Hutchmed

Target Recruit Count: 16

Registration Number: NCT05216367

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Fruquintinib Renal Impairment Study

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Fruquintinib

First Posted Date: 2022-01-31

Last Posted Date: 2023-08-01

Lead Sponsor: Hutchmed

Target Recruit Count: 24

Registration Number: NCT05216354

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: fruquintinib + sintilimab + SOX

First Posted Date: 2022-01-04

Last Posted Date: 2022-08-19

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 42

Registration Number: NCT05177068

Locations: 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Phase 2

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Fruquintinib

First Posted Date: 2021-12-02

Last Posted Date: 2022-03-02

Lead Sponsor: Fudan University

Target Recruit Count: 31

Registration Number: NCT05142631

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Phase 2

Recruiting

Conditions: GastroEsophageal Cancer
SOX
Gastric Cancer
Fruquintinib

Interventions: Drug: Fruquintinib + SOX

First Posted Date: 2021-11-16

Last Posted Date: 2024-02-26

Lead Sponsor: Guangxi Medical University

Target Recruit Count: 53

Registration Number: NCT05122091

Locations: 🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, China

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2021-08-27

Last Posted Date: 2023-04-28

Lead Sponsor: Zhen-Yu Ding

Target Recruit Count: 29

Registration Number: NCT05025631

Locations: 🇨🇳
China West Hospital, Chengdu, Sichuan, China

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: fruquintinib plus capecitabine

First Posted Date: 2021-08-23

Last Posted Date: 2022-08-18

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 48

Registration Number: NCT05016869

Locations: 🇨🇳
National Center/Cancer Hospital, China Academy of Medical Science and Peking Union Medical College, Beijing, China

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib Combined With mFOLFOX6/FOLFIRI

First Posted Date: 2021-08-13

Last Posted Date: 2022-10-26

Lead Sponsor: Zhou Fuxiang

Target Recruit Count: 43

Registration Number: NCT05004441

Locations: 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: fruquintinib plus TAS-102

First Posted Date: 2021-08-13

Last Posted Date: 2022-08-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 54

Registration Number: NCT05004831

Locations: 🇨🇳
the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy